The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Cancer Risk for Patients with Juvenile Idiopathic Arthritis Taking TNF Inhibitors

Cancer Risk for Patients with Juvenile Idiopathic Arthritis Taking TNF Inhibitors

March 20, 2017 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
A 3D rendering of a TNF alpha cytokine protein molecule, such as infliximab, adalimumab, certolizumab and etanercept.

A 3D rendering of a TNF alpha cytokine protein molecule, such as infliximab, adalimumab, certolizumab and etanercept.
molekuul_be/shutterstock.coma

WASHINGTON, D.C.—Juvenile idiopathic arthritis (JIA) patients taking TNF inhibitors don’t develop new cancers at a higher rate than JIA patients who don’t take TNF inhibitors, according to the largest study so far conducted to study the possible link.

You Might Also Like
  • TNF Inhibitors May Not Be Linked to Cancer Risk in Kids
  • TNF Inhibitors Do Not Seem to Boost Cancer-Recurrence Rates
  • New Genetic Loci Identified, Epigenome Explored in Juvenile Idiopathic Arthritis
Explore This Issue
March 2017
Also By This Author
  • HealthKit Wellness App Holds Promise for Medicine, Rheumatology

The findings were reported at the 2016 ACR/ARHP Annual Meeting in an abstract session that also included reports on osteoporosis care for rheumatoid arthritis patients and tofacitinib for psoriatic arthritis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

TNF Inhibitors & Cancer

In 2009, the FDA began labeling TNF (tumor necrosis factor) inhibitors with a warning that lymphoma and other malignancies have been reported in children and adolescents treated with them. Studies looking at cancer rates in JIA have typically included very few patients taking TNF inhibitors, but retrospective studies examining the issue have found no link between the drug and cancers.

In the study led by the University of Alabama at Birmingham, data were drawn from the U.S. Medicaid Analytic eXtract (MAX) data set from 2000 to 2010 and from U.S. Truven MarketScan claims data from 2010 to 2014.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The analysis included 27,038 JIA patients followed for a median of 1.4 years and an average of about four years. A total of 3,297 of the patients took TNF inhibitors.

Researchers found there were 20 incident malignancies—not counting nonmelanoma skin cancers—in the JIA population as a whole, which had a standardized incidence ratio of 2.4 compared with what is expected in the general population, based on Surveillance, Epidemiology, and End Results (SEER) data. There were seven incident malignancies among those taking TNF inhibitors—an SIR of 2.9 compared with what would be expected for the general population.

The results generally agree with prospective studies of adults with rheumatoid arthritis (RA) on TNF blockers, said Timothy Beukelman, MD, MSCE, associate professor of pediatric rheumatology at UAB.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“The diagnosis of JIA was associated with a subsequent increased rate of malignancy irrespective of treatment,” he said. “Malignancy rates following treatment with TNF inhibitors were similar to rates among JIA patients who did not receive TNF inhibitors.”

Tofacitinib & PsA

In another study, researchers showed for the first time that the JAK inhibitor, tofacitinib, is effective in patients with psoriatic arthritis (PsA) with active disease who have had an inadequate response to conventional synthetic disease-modifying (csDMARD) therapy. The study was sponsored by Pfizer, the drug’s manufacturer.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports Tagged With: 2016 ACR/ARHP Annual Meeting, American College of Rheumatology, Cancer, inhibitor, Juvenile idiopathic arthritis, Pediatrics, rate, Research, rheumatology, risk, TNF, TreatmentIssue: March 2017

You Might Also Like:
  • TNF Inhibitors May Not Be Linked to Cancer Risk in Kids
  • TNF Inhibitors Do Not Seem to Boost Cancer-Recurrence Rates
  • New Genetic Loci Identified, Epigenome Explored in Juvenile Idiopathic Arthritis
  • Growing Up Confident with Juvenile Idiopathic Arthritis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)